Prognostic value of nocturnal melatonin levels as a novel marker in patients with ST-segment elevation myocardial infarction.
We evaluated the possible relation between circulating levels of nocturnal melatonin, C-reactive protein, and the development of adverse cardiovascular events in patients with ST-segment elevation myocardial infarction. Patients who had developed adverse events during follow-up had significantly lower nocturnal melatonin levels than patients without events.